NK911

a polymeric micelle carrier system for doxorubicin; the NK911 micelle carrier consists of polyethyleneglycol and conjugated doxorubicin-polyaspartic acid; it has high hydrophobic inner core, and therefore can entrap the sufficient amount of doxorubicin

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Matsumura, Y: 2 articles (11/2004 - 07/2001)
2.	Deng, Chao: 1 article (12/2019)
3.	Gu, Xiaolei: 1 article (12/2019)
4.	Sun, Huanli: 1 article (12/2019)
5.	Xu, Hao: 1 article (12/2019)
6.	Zhang, Qiang: 1 article (12/2019)
7.	Zhong, Zhiyuan: 1 article (12/2019)
8.	Hamaguchi, T: 1 article (11/2004)
9.	Ikeda, M: 1 article (11/2004)
10.	Muro, K: 1 article (11/2004)

Related Diseases

1.	Neoplasms (Cancer) 07/06/2001 - "NK911 has a small particle size of about 40 nm in diameter that accumulates in tumor tissue by EPR effect showing much stronger activity than the free DOX. " 10/01/2002 - "On the other hand, DXR packed in NK911 may be distributed by diffusion to cancer cells distant from the tumor vessel, because NK911 can leak out of the tumor vessel and may be able to release free DXR more easily than Doxil. " 10/01/2002 - "It has been suggested that Doxil can deliver DXR to a solid tumor more efficiently than NK911 via the EPR (enhanced permeability and retention) effect, because Doxil may be more stable in plasma than NK911. " 10/01/2002 - "In drug distribution experiments using an in vitro solid tumor model, when spheroids formed from two human colonic cancer lines, HT-29 and WiDr, and a human stomach cancer line, MKN28, were exposed to NK911, DXR was distributed throughout the spheroids, including their center. " 12/09/2019 - "A few polypeptide-based nanoformulations (e.g., NK105, NC6004, NK911, CT2103) are under phases I-III clinical investigation for treating patients with advanced solid tumors. "
2.	Vomiting 11/15/2004 - "NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. "
3.	Stomach Neoplasms (Stomach Cancer) 10/01/2002 - "In drug distribution experiments using an in vitro solid tumor model, when spheroids formed from two human colonic cancer lines, HT-29 and WiDr, and a human stomach cancer line, MKN28, were exposed to NK911, DXR was distributed throughout the spheroids, including their center. "
4.	Nausea 11/15/2004 - "NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. "
5.	Colonic Neoplasms (Colon Cancer) 10/01/2002 - "In drug distribution experiments using an in vitro solid tumor model, when spheroids formed from two human colonic cancer lines, HT-29 and WiDr, and a human stomach cancer line, MKN28, were exposed to NK911, DXR was distributed throughout the spheroids, including their center. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	demplatin pegraglumer
3.	paclitaxel poliglumex (XYOTAX)
4.	NK105
5.	liposomal doxorubicin (Doxil)

Related Therapies and Procedures

1.	Therapeutics